KP Tissue Q2 Earnings Call Highlights

KP Tissue reported higher Q2 revenue and adjusted EBITDA, driven by stronger U.S. sales volumes, improved performance at its Memphis facility, and lower pulp prices. Management guided for Q3 adjusted EBITDA to stay in line with CAD 90.6 million generated in Q2, suggesting steady near-term earnings power.

Analysis

Near term, the market should read this as a margin confirmation story rather than a top-line breakout. Lower pulp is a temporary input-cost tailwind, but the more important signal is that the business appears to be converting incremental U.S. volume into EBITDA instead of sacrificing it through promotions or logistics friction. If Memphis is now running closer to design capacity, that creates operating leverage that can persist for several quarters even if sales growth normalizes.

Relative winners are the tissue channels where KPT is competing on value and shelf presence: a stronger North American footprint can force regional/private-label rivals to defend share with price or trade spend, while the large branded incumbents likely feel less direct pressure but may see discipline improve across the category. The second-order effect is that lower pulp tends to lift the whole sub-sector, but the names with the cleanest manufacturing execution and U.S. mix should outperform because they capture both cost relief and mix uplift. That makes this more interesting as a relative-value trade than as a standalone beta call.

The key risk is that the quarter may be peaking off easy comps: if pulp bottoms and starts rising, or if U.S. volume was inventory replenishment rather than end-demand, EBITDA can mean-revert quickly. Over 1-3 months, the catalyst is whether management can hold the Q3 run-rate; over 6-18 months, the question is whether Memphis improvements are structural or just a one-off efficiency catch-up. I would watch for any sequential deterioration in adjusted EBITDA margin or signs that promotional intensity has had to increase to sustain volumes.

Key Decisions for Investors

• Lean long KPT.TO on any post-print weakness if the stock is not already discounting the Q3 run-rate; the setup is 1-2 quarters of margin support with limited need for heroic sales growth. Falsify if Q3 adjusted EBITDA falls materially below the implied CAD 90.6M run-rate.
• Prefer a relative-value long KPT.TO / short a broader Canadian consumer-staples or paper-packaging proxy if available; the thesis is that execution plus lower pulp should outperform pure cost beta over the next 1-3 months.
• Use pulp prices as the key monitor: if benchmark pulp reverses higher, trim or hedge the position because the earnings tailwind can unwind faster than revenue growth can offset it.
• Set an alert for any guidance change or commentary on U.S. demand versus inventory fill; if volumes slow but EBITDA holds only through inventory draw, the trade becomes a short-duration pop rather than a structural re-rate.